-
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 21:38 GMT
… Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company … first-in-class, oral somatostatin receptor type 2 (SST2 … studies for the treatment of congenital adrenal … resulting from in-house drug discovery efforts, including …
-
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 20:05 GMT
… late-stage clinical trials in acromegaly … Drug Administration (FDA) seeking regulatory approval of paltusotine for the treatment … PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical … -in-class, oral somatostatin receptor type 2 …
-
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
08 May 2024 20:05 GMT
… Trial
Data from Phase 3 PATHFNDR 1 and 2 Trials … development for the treatment of people with … Investigational Oral Small Molecule Somatostatin Receptor Ligand for … CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company …
-
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
02 May 2024 20:05 GMT
… =4756f5f4c0 About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical … first-in-class, oral somatostatin receptor type 2 (SST2 … clinical studies for the treatment of congenital adrenal … resulting from in-house drug discovery efforts, including …
-
FDA Roundup: April 30, 2024
30 Apr 2024 22:20 GMT
… 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine … the first FDA approval of a systemic therapy for the treatment of … veterinary drugs, vaccines and other biological products for human use, and medical …
-
FDA Roundup: April 30, 2024
30 Apr 2024 19:58 GMT
… 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine … the first FDA approval of a systemic therapy for the treatment of … veterinary drugs, vaccines and other biological products for human use, and medical …
-
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
30 Apr 2024 11:00 GMT
… U.S. Food and Drug Administration (“FDA”) to participate in … developed for the treatment and diagnosis of somatostatin receptor subtype 2 … results in later clinical trials; clinical trial results may not … mandated by the FDA for additional trials, Phase 1 and …
-
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
27 Apr 2024 14:52 GMT
… insurance after they receive treatment for commercially insured patients, … there had been no medicines approved for patients with … of age and older with somatostatin receptor-positive (SSTR+) … request any new clinical trials or clinical data to …
-
FDA Roundup: April 26, 2024
26 Apr 2024 23:51 GMT
… 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine … the first FDA approval of a systemic therapy for the treatment of … veterinary drugs, vaccines and other biological products for human use, and medical …
-
Week in review: FDA approvals, CRL for DEB, and more
26 Apr 2024 23:30 GMT
… recessive dystrophic epidermolysis bullosa treatment
Abeona's pz … full article.
3.) FDA approves tovorafenib for most … .
4.) First radioactive drug approved for patients 12 … FDA has approved lutetium Lu 177 dotatate for pediatric patients with somatostatin …